TOP - May 2018, Vol 11, No 1

At the 2018 Hematology/Oncology Pharmacy Association Annual Conference, Jaime Anderson, PharmD, BCOP, reviewed recent efficacy and safety data on immune checkpoint inhibitor regimens in melanoma, and discussed disease-specific characteristics that may guide treatment-planning decisions.

According to the results of 2 separate clinical trials presented at the 2018 Genitourinary Cancers Symposium, apalutamide and enzalutamide reduced the risk for metastasis and prolonged metastasis-free survival in patients with nonmetastatic castrate-resistant prostate cancer.

At the 2018 Cancer Survivorship Symposium, Katy K. Tsai, MD, suggested that cancer treatment with immunotherapy warrants special consideration from a survivorship standpoint because of its novel mechanisms of action, extended treatment periods, and unique toxicities.

Interim data from a recent clinical trial of nelipepimut-S plus trastuzumab showed a disease-free survival advantage compared with trastuzumab alone in patients with HER2 1+/2+ breast cancer.

In the May issue of The Oncology Pharmacist, we feature highlights of key presentations and studies from the 2018 Hematology/Oncology Pharmacy Association (HOPA) Annual Conference, which took place in Denver, CO.

At the 2018 Hematology/Oncology Pharmacy Association Annual Conference, Dr Seddon provided attendees with an overview of FLT3-mutated AML, including currently available treatments, mechanisms of resistance, and future directions.

At the 2018 Hematology/Oncology Pharmacy Association Annual Conference, Josiah Land, PharmD, BCOP, and Jacob Kettle, PharmD, BCOP, discussed the realities of using PD-L1 as a biomarker in oncology in the front- and second-line settings.

At the 2018 Genitourinary Cancers Symposium, lead investigator Alison Jane Birtle, MD, MBBS, MRCP, FRCR, presented the results of the phase 3 POUT clinical trial which showed that adjuvant chemotherapy had impressive gains in the disease-free survival and metastasis-free survival in upper-tract urothelial cancer.

Although it is very curable when found and treated early on, early-stage cervical cancer may not cause any noticeable signs or symptoms.

Progression-free survival (PFS) was extended by 3.5 months with first-line atezolizumab (Tecentriq) plus bevacizumab (Avastin) in patients with metastatic renal-­cell carcinoma (RCC) versus standard-of-care sunitinib (Sutent) in the phase 3 IMmotion151 clinical trial presented at the 2018 Genitourinary Cancers Symposium